CalciMedica, Inc. (CALC)

NASDAQ: CALC · IEX Real-Time Price · USD
4.250
+0.080 (1.92%)
Jul 19, 2024, 11:18 AM EDT - Market open
1.92%
Market Cap 45.69M
Revenue (ttm) n/a
Net Income (ttm) -14.94M
Shares Out 10.75M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,224
Open 4.140
Previous Close 4.170
Day's Range 4.050 - 4.340
52-Week Range 1.750 - 8.380
Beta n/a
Analysts Strong Buy
Price Target 20.50 (+382.35%)
Earnings Date Aug 8, 2024

About CALC

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an or... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CALC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CALC stock is "Strong Buy." The 12-month stock price forecast is $20.5, which is an increase of 382.35% from the latest price.

Price Target
$20.5
(382.35% upside)
Analyst Consensus: Strong Buy

News

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or th...

10 days ago - PRNewsWire

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release...

11 days ago - PRNewsWire

CalciMedica Set to Join Russell Microcap® Index

LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-...

18 days ago - PRNewsWire

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper...

22 days ago - PRNewsWire

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m.

22 days ago - PRNewsWire

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to in...

2 months ago - PRNewsWire

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedic...

2 months ago - PRNewsWire

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Full target enrollment of 216 patients achieved  Topline data from CARPO expected in 2Q 2024  LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinic...

3 months ago - PRNewsWire

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024  Auxora granted Investigational New Drug clearance by the FDA for Phase 2 tria...

4 months ago - PRNewsWire

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical obse...

4 months ago - PRNewsWire

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate LA JOLLA, Calif. , Feb. 28, 2024 /PRNewswire/ -- C...

5 months ago - PRNewsWire

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a c...

5 months ago - PRNewsWire

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

LA JOLLA, Calif. , Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calciu...

5 months ago - PRNewsWire

CalciMedica Announces Private Placement of up to Approximately $55 Million

$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million Upfront net proceeds to provide fun...

6 months ago - PRNewsWire

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Continued expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT); data from initial cohort to be presented at 65th Annual  American Society of Hematology (ASH...

9 months ago - PRNewsWire

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Auxora ™  showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (ICU) days and eliminated the need for total parenteral nutrition (TPN) LA JOLLA, Calif. , Nov. 2, 2023 /PR...

9 months ago - PRNewsWire

CalciMedica Announces Upcoming Presentations and Events in September

LA JOLLA, Calif. , Sept. 6, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...

11 months ago - PRNewsWire

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

LA JOLLA, Calif. , Aug. 31, 2023 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calci...

11 months ago - PRNewsWire

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a clini...

1 year ago - GlobeNewsWire

CalciMedica Announces Relisting on Nasdaq

LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infl...

1 year ago - GlobeNewsWire

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP

1 year ago - GlobeNewsWire

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimat...

1 year ago - GlobeNewsWire

CalciMedica Expands Executive Team with New Appointments

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cun...

1 year ago - GlobeNewsWire

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infla...

1 year ago - GlobeNewsWire

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected...

1 year ago - GlobeNewsWire